Source comparison
PT-141 vs Flibanserin vs PDE5 Inhibitors: Mechanism Comparison
PT-141 (bremelanotide) MC4R agonist in hypothalamus; increases dopamine and oxytocin, reduces prolactin Central nervous system—paraventricular nucleus 45–90 minutes 6–12 hours Phase 3 RCT (FDA-approved for HSDD in women) Flibanserin (Addyi) 5-HT1A agonist and
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist in hypothalamus; increases dopamine and oxytocin, reduces prolactin
- Central nervous system—paraventricular nucleus
- 45–90 minutes
- 6–12 hours
- Phase 3 RCT (FDA-approved for HSDD in women)
- Flibanserin (Addyi)
- 5-HT1A agonist and 5-HT2A antagonist; modulates serotonin, dopamine, norepinephrine balance
- Central nervous system—prefrontal cortex and limbic regions
- 4–8 weeks (chronic dosing required)
- Chronic effect
- Sildenafil (Viagra)
- PDE5 inhibitor; prevents cGMP breakdown, enhancing nitric oxide-mediated smooth muscle relaxation
- Peripheral vascular tissue—corpora cavernosa
- 30–60 minutes
- 4–6 hours
- Phase 3 RCT (FDA-approved for ED in men)
- Tadalafil (Cialis)
- PDE5 inhibitor; same mechanism as sildenafil with longer half-life
- 24–36 hours
- Testosterone replacement
- Androgen receptor agonist; restores baseline sexual interest via multiple pathways
- Central and peripheral—hypothalamus, muscle, adipose
- 2–6 weeks
- Clinical guideline-supported for hypogonadism
- Professional Assessment
- PT-141 uniquely targets sexual motivation at the CNS level without requiring chronic dosing or relying on vascular mechanisms. It fills a gap for subjects who experience low desire despite normal vascular function—complementary to, not redundant with, PDE5 inhibitors.